News | Molecular Imaging | December 07, 2021

Ascelia Pharma AB presented a study in which Orviglance (manganese chloride tetrahydrate, former working name Mangoral) was compared against a gadolinium-based contrast agent at RSNA 2021

Carl Bjartmar

Carl Bjartmar

December 7, 2021 — Orviglance* is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI) developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious, and potentially fatal, side effects from the currently available class of gadolinium-based contrast agents, which all carry black box warnings. Orviglance, which has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), is currently in Phase 3 development.

The comparison study versus the gadolinium contrast agent showed that Orviglance enhanced MRI was as effective as the gadolinium contrast agent gadobenate dimeglumine (Multihance) in terms of visualization of lesions and number of detected lesions. In fact, two out of the three independent readers reported higher scores for Orviglance-enhanced MRI. The results also showed that Orviglance-enhanced MRI provides improved diagnostic efficacy compared to MRI without a contrast agent using identical endpoints, as in the ongoing pivotal Phase 3 study, SPARKLE.

SPARKLE is a global multicenter study of Orviglance in up to 200 patients with severe rena impairment and known or suspected focal liver lesions. Primary efficacy, in terms of lesion visualization compared to unenhanced MRI (MRI without a contrast agent), will be evaluated by three independent blinded readers. Two supporting studies aim to provide further data about the use of Orviglance in clinical practice: one study includes patients with hepatic impairment (impaired liver function) and one study to determine the effect of food intake on Orviglance uptake, for which patient recruitment has been completed.

Carl Bjartmar, chief medical officer at Ascelia Pharma, said: “We are very pleased to be presenting the study as an oral paper presentation at the prestigious Radiological Society of North America’s radiology conference, RSNA. The study provides robust evidence of the diagnostic value that Orviglance can offer once it is available to patients and physicians. Orviglance is being developed to address the unmet medical need of patients with poor kidney function who require liver imaging, and it is very encouraging that Orviglance is as effective as a gadolinium contrast agent.” 

The study was presented at the RSNA on Dec. 1, 2021, by Dr. Kohkan Shamsi.

For more information:

*Trademark is registered in Europe and several other markets and submitted for registration in the U.S. 

Related RSNA2021 content

Related Content of MRI Gadolinium Safety Concerns

The Debate Over Gadolinium MRI Contrast Toxicity

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

FDA: No Harm in MRI Gadolinium Retention in the Brain

VIDEO: MRI Gadolinium Contrast Retention in the Brain

Gadolinium May Remain in Brain After Contrast MRI

Related Content

Feature | Radiology Business | By Jef Williams

The Great Resignation has impacted every industry, including ours. While this movement will be studied for years to come ...

Time January 20, 2022
Feature | Vendor Neutral Archive (VNA)

Vendor neutral archives (VNAs) have become a staple within the healthcare IT system. At the Radiological Society of ...

Time January 20, 2022
Sponsored Content | Case Study | Ultrasound Imaging

The most common cause of chronic liver disease? Nonalcoholic fatty liver disease (NAFLD). With 25% of the world’s ...

Time January 19, 2022
Videos | Artificial Intelligence

Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by ...

Time January 13, 2022
Videos | Enterprise Imaging

Steve Holloway, company director at Signify Research, explains the trends he has seen over the past couple years in ...

Time January 13, 2022
News | Radiology Imaging

January 12, 2022 — Machine-learning methods are being actively developed for computed imaging systems like magnetic ...

Time January 12, 2022
News | Breast Imaging

January 11, 2022 — Less-experienced radiologists are more likely to recommend additional imaging for women undergoing ...

Time January 11, 2022
News | PET Imaging

January 11, 2022 — Clario, a technology company that delivers the leading endpoint technology solutions for clinical ...

Time January 11, 2022
News | Molecular Imaging

Janaury 10, 2022 — The Department of Energy’s National Nuclear Security Administration (NNSA) and Office of ...

Time January 10, 2022
News | Computed Tomography (CT)

January 6, 2022 — Royal Philips announced new additions to its CT imaging portfolio at the Radiological Society of North ...

Time January 06, 2022
Subscribe Now